An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Autonomix Medical, Inc. (NASDAQ: AMIX) has partnered with NoiseFigure Research, Inc. to enhance its ASIC microchip for human clinical testing and commercial production. The collaboration aims to revolutionize nerve system disease diagnosis and treatment. The proprietary ASIC technology promises superior nerve signal detection and localization, with 3000 times greater sensitivity than existing solutions. Autonomix's catheter-based technology targets neural signals associated with pain or disease, offering a more precise and effective alternative to current treatment methods. The initial focus is on addressing pancreatic cancer-related pain.
Autonomix Medical, Inc. (NASDAQ: AMIX) ha collaborato con NoiseFigure Research, Inc. per migliorare il suo microchip ASIC destinato ai test clinici umani e alla produzione commerciale. La collaborazione mira a rivoluzionare la diagnosi e il trattamento delle malattie del sistema nervoso. La tecnologia ASIC proprietaria garantisce un rilevamento e una localizzazione dei segnali nervosi notevolmente superiori, con una sensibilità 3000 volte maggiore rispetto alle soluzioni esistenti. La tecnologia basata su cateteri di Autonomix si concentra sui segnali neurali associati a dolore o malattie, offrendo un'alternativa più precisa ed efficace ai metodi di trattamento attuali. L'obiettivo iniziale è affrontare il dolore correlato al cancro del pancreas.
Autonomix Medical, Inc. (NASDAQ: AMIX) se ha asociado con NoiseFigure Research, Inc. para mejorar su microchip ASIC para pruebas clínicas en humanos y producción comercial. La colaboración busca revolucionar el diagnóstico y tratamiento de enfermedades del sistema nervioso. La tecnología ASIC propietaria promete una detección y localización de señales nerviosas superior, con una sensibilidad 3000 veces mayor que las soluciones existentes. La tecnología de catéteres de Autonomix se enfoca en señales neuronales asociadas con dolor o enfermedad, ofreciendo una alternativa más precisa y efectiva que los métodos de tratamiento actuales. El enfoque inicial está en abordar el dolor relacionado con el cáncer de páncreas.
Autonomix Medical, Inc. (NASDAQ: AMIX)가 NoiseFigure Research, Inc.와 협력하여 인체 임상 시험 및 상업 생산을 위한 ASIC 마이크로칩을 강화하고 있습니다. 이 협력은 신경계 질환의 진단 및 치료를 혁신할 것을 목표로 합니다. 독자적인 ASIC 기술은 기존 솔루션보다 3000배 높은 민감도로 신경 신호 검출 및 위치를 약속합니다. Autonomix의 카테터 기반 기술은 통증 또는 질병과 관련된 신경 신호를 대상으로 하여 현재 치료 방법보다 더 정확하고 효과적인 대안을 제공합니다. 초기 초점은 췌장암 관련 통증을 다루는 것입니다.
Autonomix Medical, Inc. (NASDAQ: AMIX) s'est associée à NoiseFigure Research, Inc. pour améliorer son microchip ASIC destiné aux tests cliniques humains et à la production commerciale. La collaboration a pour but de révolutionner le diagnostic et le traitement des maladies du système nerveux. La technologie ASIC propriétaire promet une détection et une localisation des signaux nerveux nettement supérieure, avec une sensibilité 3000 fois plus grande que les solutions existantes. La technologie à base de cathéters d'Autonomix cible les signaux neuronaux associés à la douleur ou à la maladie, offrant une alternative plus précise et efficace aux méthodes de traitement actuelles. L'objectif initial est de s'attaquer à la douleur liée au cancer du pancréas.
Autonomix Medical, Inc. (NASDAQ: AMIX) hat sich mit NoiseFigure Research, Inc. zusammengetan, um seinen ASIC-Mikrochip für klinische Tests am Menschen und die kommerzielle Produktion zu verbessern. Die Zusammenarbeit zielt darauf ab, die Diagnose und Behandlung von Erkrankungen des Nervensystems zu revolutionieren. Die proprietäre ASIC-Technologie verspricht eine überlegene Erkennung und Lokalisierung von Nervensignalen mit einer 3000-mal höheren Empfindlichkeit als bestehende Lösungen. Die katheterbasierte Technologie von Autonomix zielt auf neuronale Signale ab, die mit Schmerzen oder Krankheiten verbunden sind, und bietet eine präzisere und effektivere Alternative zu aktuellen Behandlungsmethoden. Der anfängliche Fokus liegt auf der Behandlung von schmerzen, die mit Bauchspeicheldrüsenkrebs in Verbindung stehen.
Positive
None.
Negative
None.
Insights
Autonomix's service agreement with NoiseFigure Research, Inc. represents a significant step forward in the development of their second-generation ASIC microchip technology. This partnership is expected to enhance the capability of the microchip which is central to the performance of their catheter-based technology for neural signal detection and pain management. The proprietary ASIC microchip's ability to detect neural activity with substantially higher sensitivity compared to existing technologies could translate into a competitive advantage for Autonomix in the medical device market. As they move towards human clinical trials and commercial production, the success of these advancements could potentially disrupt current pain management protocols that rely heavily on pharmaceuticals, offering a more targeted and less invasive alternative. For investors, this collaboration could be a signal of maturation in Autonomix's R&D cycle. However, the realization of returns on this investment will likely hinge on successful clinical trial outcomes and the subsequent adoption of the technology by healthcare practitioners.
Entering into a high-caliber tech development agreement is indicative of Autonomix's commitment to innovation in the treatment of diseases involving the nervous system. The focus on pancreatic cancer-related pain, a field with significant unmet medical needs, positions the company in a potentially lucrative niche market. Despite the opportunity, investors should be aware of the inherent risks associated with the biotechnology sector, such as regulatory hurdles, the need for continuous funding to sustain long R&D periods and market adoption challenges. The company’s strategic move to address issues with current pain management approaches, primarily opioid dependency and invasive procedures, if successful, could see Autonomix gaining early mover advantage. Moreover, the reliance on advanced ASIC microchip technology underlines the importance of tech integration in next-generation medical devices, a trend that investors may find increasingly prevalent across the biotech landscape.
The collaboration between Autonomix and NoiseFigure Research falls into a critical phase of medical device development—pre-clinical assessments and preparations for human trials. These stages are important for ensuring safety, efficacy and optimization of the technology before pivotal trials. The second-generation ASIC microchip's development suggests an incremental innovation approach, aiming to refine the device's capabilities for better outcomes. From a clinical perspective, the anticipated sensitivity of the microchip in detecting neural activity could be a game-changer in pain management, potentially leading to more precise and effective treatments with fewer side effects. While the implications of this technology for patients are profound, especially in the domain of cancer-related pain management, the path to market will require rigorous clinical validation. The planned pivotal trial in 2025 will be a major milestone for Autonomix and positive results could significantly impact the company’s valuation and market potential.
THE WOODLANDS, TX, April 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has entered into a service agreement with NoiseFigure Research, Inc. (NFR), a premier application specific integrated circuits (ASICs) service provider.
As part of the agreement, Autonomix will work with NFR to assess its ASIC microchip and upgrade the chip to its second-generation in preparation for human clinical testing in the Company’s planned pivotal trial in 2025. Additionally, NFR will evaluate a subsequent version meant to enable commercial production volumes.
Lori Bisson, Chief Executive Officer of Autonomix said, “This collaboration with NFR is an important step in the evolution of our technology and simple approach to a procedure for pain management and other indications. The proprietary ASIC is the real intelligence in our technology that enables us to detect neural activity, amplify nerve signals, convert signals to digital form, and geolocate nerves, with approximately 3000 times greater sensitivity than the closest available sensing technology in the market today. We look forward to working closely with the NFR team and leveraging their expertise.”
The Company’s catheter-based technology is being developed to do two things: sense neural signals associated with pain or disease and precisely target those nerves for treatment. Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body.
The Company is initially developing its technology to address pancreatic cancer-related pain. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects. For more information about the Company’s technology, please visit autonomix.com.
About NoiseFigure Research, Inc.
NFR is a leader in democratizing access to application-specific integrated circuit (ASIC) services in addition to recent offerings into the manufacturing of PCBs, substrates, and flexible electronics. Since our inception in 2009, NFR has been dedicated to empowering developers with world-class custom ASICs and ASIC services. Our expertise spans Analog, RF/uWave, and Mixed Signal chip design, including packaging and related materials. By adding PCB, substrate, and flexible electronics manufacturing to our portfolio, we further lower the barriers for innovation. Our products and services cater to a wide range of industries, including Commercial, Military, Government, and Aerospace, enabling customers to realize their visions. We are deeply committed to supporting our customers' endeavors and are excited to continue driving advancements in technology and manufacturing.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward looking statements in this press release include, without limitation, the timing of the Company’s planned pivotal trial. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’
Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact JTC Team, LLC Jenene Thomas 833-475-8247 autonomix@jtcir.com
FAQ
What is the purpose of Autonomix's collaboration with NoiseFigure Research, Inc.?
Autonomix has partnered with NoiseFigure Research, Inc. to enhance its ASIC microchip for human clinical testing and commercial production.
How does Autonomix's proprietary ASIC technology differ from existing solutions?
Autonomix's ASIC technology offers 3000 times greater sensitivity for nerve signal detection and localization than current technologies.
What is the focus of Autonomix's catheter-based technology development?
Autonomix's catheter-based technology targets neural signals associated with pain or disease, providing a precise alternative to current treatment methods.
Which medical condition is Autonomix initially targeting with its technology?
Autonomix is initially focusing on addressing pancreatic cancer-related pain with its technology.
